Dxcover Earns CE-IVDR Certification

Dxcover’s breakthrough liquid biopsy medical device has achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR).

“This validates not just a single product, but the underlying rigor of our infrastructure—from software architecture and data pipelines to clinical evidence and quality processes,” Dxcover Co-Founder/CEO Matthew Baker Ph.D., said. “It de-risks Dxcover’s ability to scale its technology across multiple clinical applications, an important step in furthering Dxcover’s mission to detect cancer early and benefit patients.”

Dxcover is leveraging artificial intelligence (AI) and machine learning into its IVDR-compliant Class C medical device software. CE marking for a Class C device is granted to diagnostic devices that deliver results highly significant for patient care and treatment decisions. Achieving CE-IVDR Class C status reflects compliance with one of the most stringent regulatory standards in Europe.

“Dxcover’s technology represents a step-change in diagnostic approach. But disruptive innovation can only be realized in practice when subject to the highest levels of regulatory scrutiny, which is why we are delighted to have reached this milestone,” Dxcover General Manager David Eustace Ph.D., stated. “This high-impact certification provides the most solid of regulatory foundations to support commercialization and future growth.”

Dxcover is changing how early, accurately, and efficiently cancer can be detected. The Scottish company’s platform integrates infrared spectroscopy data with proprietary algorithms to deliver earlier, more actionable clinical insights from a small amount of blood, yielding results in hours rather than weeks.